TY - JOUR
T1 - Pulmonary Abnormalities in Liver Disease
T2 - Relevance to Transplantation and Outcome
AU - Raevens, Sarah
AU - Boret, Maxine
AU - De Pauw, Michel
AU - Fallon, Michael B.
AU - Van Vlierberghe, Hans
N1 - Publisher Copyright:
© 2021 by the American Association for the Study of Liver Diseases.
PY - 2021/9
Y1 - 2021/9
N2 - Pulmonary disease in liver cirrhosis and portal hypertension (PH) constitutes a challenging clinical scenario and may have important implications with regard to prognosis, liver transplantation (LT) candidacy, and post-LT outcome. Pre-LT evaluation should include adequate screening for pulmonary diseases that may occur concomitantly with liver disease as well as for those that may arise as a complication of end-stage liver disease and PH, given that either may jeopardize safe LT and successful outcome. It is key to discriminate those patients who would benefit from LT, especially pulmonary disorders that have been reported to resolve post-LT and are considered “pulmonary indications” for transplant, from those who are at increased mortality risk and in whom LT is contraindicated. In conclusion, in this article, we review the impact of several pulmonary disorders, including cystic fibrosis, alpha 1-antitrypsin deficiency, hereditary hemorrhagic telangiectasia, sarcoidosis, coronavirus disease 2019, asthma, chronic obstructive pulmonary disease, pulmonary nodules, interstitial lung disease, hepatic hydrothorax, hepatopulmonary syndrome, and portopulmonary hypertension, on post-LT survival, as well as the reciprocal impact of LT on the evolution of lung function.
AB - Pulmonary disease in liver cirrhosis and portal hypertension (PH) constitutes a challenging clinical scenario and may have important implications with regard to prognosis, liver transplantation (LT) candidacy, and post-LT outcome. Pre-LT evaluation should include adequate screening for pulmonary diseases that may occur concomitantly with liver disease as well as for those that may arise as a complication of end-stage liver disease and PH, given that either may jeopardize safe LT and successful outcome. It is key to discriminate those patients who would benefit from LT, especially pulmonary disorders that have been reported to resolve post-LT and are considered “pulmonary indications” for transplant, from those who are at increased mortality risk and in whom LT is contraindicated. In conclusion, in this article, we review the impact of several pulmonary disorders, including cystic fibrosis, alpha 1-antitrypsin deficiency, hereditary hemorrhagic telangiectasia, sarcoidosis, coronavirus disease 2019, asthma, chronic obstructive pulmonary disease, pulmonary nodules, interstitial lung disease, hepatic hydrothorax, hepatopulmonary syndrome, and portopulmonary hypertension, on post-LT survival, as well as the reciprocal impact of LT on the evolution of lung function.
UR - http://www.scopus.com/inward/record.url?scp=85106280673&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85106280673&partnerID=8YFLogxK
U2 - 10.1002/hep.31770
DO - 10.1002/hep.31770
M3 - Review article
C2 - 33636019
AN - SCOPUS:85106280673
SN - 0270-9139
VL - 74
SP - 1674
EP - 1686
JO - Hepatology
JF - Hepatology
IS - 3
ER -